Endometriosis

DotLab announces three granted patents for its non-invasive test for endometriosis, DotEndo™

Retrieved on: 
Friday, August 19, 2022 - 1:24am

Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.

Key Points: 
  • Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.
  • The inventions embodied in the portfolio of granted patents U.S. Patent No.
  • 11,315,660 B2 also include the company's proprietary machine learning algorithms to detect, predict, diagnose, and monitor the presence or absence of the disease.
  • EMPOWER is the most robust clinical study of its type ever performed, making it an excellent foundation for thecommercial test.

Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay

Retrieved on: 
Thursday, August 18, 2022 - 9:05pm

AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira), a bio-analytical based womens health company focused on gynecologic disease, today announced that it will host a key opinion leader (KOL) webinar on womens health and ovarian cancer risk assessments utilizing multivariant index assays on Wednesday, August 24, 2022 at 12:00pm Eastern Time.

Key Points: 
  • AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira), a bio-analytical based womens health company focused on gynecologic disease, today announced that it will host a key opinion leader (KOL) webinar on womens health and ovarian cancer risk assessments utilizing multivariant index assays on Wednesday, August 24, 2022 at 12:00pm Eastern Time.
  • He will discuss how Aspiras soon-to-be-launched OVAWatchTM multivariate index assay diagnostic risk assessment may benefit women with pelvic masses who are not planned for surgery.
  • About Aspira Womens Health Inc.
    Aspira Womens Health Inc. is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.
  • Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.

PAINWeek 2022 Announces the Return of the International Pelvic Pain Society Track on September 8

Retrieved on: 
Thursday, August 18, 2022 - 11:00am

MONTCLAIR, N.J., Aug. 18, 2022 /PRNewswire-PRWeb/ -- Worldwide, an estimated 26% of women have chronic pelvic pain (CPP). In the US, it's the reason for 40% of laparoscopies and 12% of hysterectomies annually, even though, in 80% of the patients, the origin of the pain is not gynecologic![1] Up to a third of women have repeated absences from work due to their pain.[2] One study found that 15% of US women of childbearing age say their pelvic pain has lasted at least 6 months.[3]

Key Points: 
  • [2] One study found that 15% of US women of childbearing age say their pelvic pain has lasted at least 6 months.
  • At the PAINWeek National Conference, September 6-9 at The Cosmopolitan of Las Vegas, the IPPSInternational Pelvic Pain SocietyTrack will provide the resources and knowledge to help attendees better understand pelvic pain.
  • The IPPS Track on Thursday, September 8, will include Dr. Georgine Lamvu presenting One Candle, Two Wicks: Managing Female Sexual Pain and Dysfunction.
  • Dr. Lamvu commented, "gender specific pain conditions, such as endometriosis and female sexual pain, contribute their own unique complexity to the evaluation and management of chronic pain.

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Tuesday, August 16, 2022 - 9:30pm

The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.

Key Points: 
  • The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
  • The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 120,550 common shares ofMyovant.
  • The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

US Fertility welcomes reproductive endocrinologist, Johanna Archer, V.M.D., M.S., M.D., to the Shady Grove Fertility (SGF) Jones Institute physician team

Retrieved on: 
Tuesday, August 16, 2022 - 8:30pm

NORFOLK, Va., Aug. 16, 2022 /PRNewswire-PRWeb/ -- US Fertility, the nation's largest partnership of physician-owned and physician-led top-tier fertility practices, welcomes Johanna Archer, V.M.D., M.S., M.D., to Shady Grove Fertility's (SGF) Jones Institute in Norfolk, Virginia. Dr. Archer is now scheduling new patient appointments.

Key Points: 
  • She then completed her residency in OB/GYN at the Medical University of South Carolina in Charleston, South Carolina.
  • From there, Dr. Archer trained in REI at the University of California in San Diego, California.
  • During this time, Dr. Archer was recognized for her excellence in research by the American Society for Reproductive Medicine (ASRM).
  • SGF is among the founding partner practices of US Fertility , the largest physician-led partnership of top-tier fertility practices in the U.S.

LOONI LAUNCHES WELLNESS SOLUTIONS TO SUPPORT AND IMPROVE MENSTRUAL HEALTH

Retrieved on: 
Wednesday, August 10, 2022 - 3:12pm

NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Looni, the new women's health company, is pleased to announce the launch of its first menstrual-health product, Balance Beam Mood Complex, available online at looni.co.

Key Points: 
  • "We identified a strong need for research-backed solutions and education in the menstrual wellness space, alongside a team that was not afraid to tackle outdated taboos," says Looni co-founder Chelsea Leyland.
  • "After more than 70 years of pharmaceutical solutions that do not address the root causes of menstrual discomforts, today's women deserve better, more thoughtful solutions.
  • Looni believes in menstrual literacy and autonomythe menstrual cycle is a valuable guide to our overall health and wellbeing and Looni provides the tools and knowledge for people to become intimate with their natural rhythms.
  • Looni has created a suite of products targeting menstrual discomfort, such as mood instability and breast tenderness.

Aspira Women’s Health Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022 - 12:30pm

AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • ET
    AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira) (Nasdaq: AWH), a bio-analytical based womens health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2022.
  • Highlights of Second Quarter 2022 vs. Second Quarter 2021
    Product revenue for the three months ended June 30, 2022 was $2.0 million compared to $1.7 million for the same period in 2021, an increase of 17%.
  • Highlights of Second Quarter 2022 vs. First Quarter 2022:
    Product revenue was $2.0 million for the three months ended June 30, 2022, compared to $1.8 million for the three months ended March 31, 2022, an increase of 10%.
  • Aspira utilized $6.4 million in the second quarter of 2022, compared to $10.3 million in the first quarter of 2022 and $6.4 million for the second quarter of 2021.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Aspira Women’s Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10

Retrieved on: 
Monday, August 1, 2022 - 1:00pm

About Aspira Womens Health Inc.

Key Points: 
  • About Aspira Womens Health Inc.
    Aspira Womens Health Inc. is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.
  • Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.
  • With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health is working to deliver a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research.
  • To improve patient accessibility, Aspira Womens Health has recently launched our Aspira SynergyTM technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house.

Insights on Global Women's Health App Market Size & Share to Reach USD 6611.54 Million by 2028, Exhibit a CAGR of 19.10% | Industry Trends, Value, Analysis & Forecast Report by Zion Market Research

Retrieved on: 
Friday, July 29, 2022 - 4:30pm

The women's health app has numerous trackers, including ones for menstruation, pregnancy, and general female health.

Key Points: 
  • The women's health app has numerous trackers, including ones for menstruation, pregnancy, and general female health.
  • Additionally, there are many different women's health apps available, including a tracker for women's periods & fertility, a pregnancy app, and a birth control app.
  • Through a range of women's health applications made possible by current technology, women's health concerns are better managed.
  • The increased penetration of smartphones and the rising prevalence of disorders among women are anticipated to fuel the global women's health app market expansion.